Abstract

Supplementation with ready-to-use therapeutic food has no effect on adverse outcomes among undernourished children aged 6-59ÔÇ»months with severe pneumonia

Nalwanga, D. Giallongo, E. Musiime, V. Kiguli, S. Olupot, P. O. Alaroker, F. Opoka, R. Tagoola, A. Hamaluba, M. Mogaka, C. Nabawanuka, E. Karamagi, C. Briend, A. Maitland, K.
Front Nutr. 2025; 121507360

Permanent descriptor

https://doi.org/10.3389/fnut.2025.1507360

OBJECTIVES: To investigate the effect of supplementation with ready-to-use therapeutic food (RUTF) on adverse outcomes among undernourished children aged 6-59ÔÇ»months with severe pneumonia. METHODS: This secondary analysis of the COAST-Nutrition (ISRCTN10829073) included children hospitalized for severe pneumonia in Uganda and Kenya. Undernutrition was defined as having either a weight-for-age z score, height-for-age z score, or weight-for-height/length z score below the median of the WHO reference population (< 0) or mid-upper arm circumference (MUAC) below 13.5ÔÇ»cm. Participants were randomized to receive 1 sachet of RUTF daily for 8ÔÇ»weeks in addition to the usual diet (intervention) or usual diet alone (control). The primary composite outcome for adverse events was any one of mortality, re-admission, or deterioration of nutritional status by day 90 of follow-up. RESULTS: Of 846 main trial participants, 741 (88%) met the inclusion criteria (intervention: 374 versus control: 367). Of 687 (93%) participants in whom the primary outcome was assessed, 370 (54%) experienced an adverse event, [intervention: 184/348 (53%) versus control: 186/339(54%)]. There was no difference in the primary outcome between groups, aOR 0.92 (95% CI 0.68, 1.24), pÔÇ»=ÔÇ»0.572. Adverse outcome risk reduced with increasing age, aOR 0.53, (95% CI 0.45, 0.62), pÔÇ»<ÔÇ»0.001. CONCLUSION: RUTF supplementation did not reduce the high frequency of adverse outcomes in children aged 6-59ÔÇ»months following hospital admission with severe pneumonia. Nutritional support directly targeting metabolic needs post-pneumonia should be considered in the future. CLINICAL TRIAL REGISTRATION: ISRCTN10829073, PACTR202106635355751.